[ad_1]
Article content material
Nyxoah Appoints Dr. Maurits S. Boon, MD as Chief Medical Officer
Mont-Saint-Guibert, Belgium – April 11, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Firm”), a medical know-how firm centered on the event and commercialization of modern options to deal with Obstructive Sleep Apnea (OSA), in the present day introduced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer.
Article content material
Dr. Boon joins Nyxoah from the Thomas Jefferson College, the place he’ll proceed half time as a professor and Vice Chairman, Training. He’s twin board-certified in otolaryngology – head and neck surgical procedure, in addition to sleep medication. Dr. Boon is certainly one of two sleep surgeons with Jefferson Well being to pioneer using hypoglossal nerve stimulation remedy (HGNS) and is internationally acknowledged as some of the skilled surgeons performing HGNS procedures. He has lectured worldwide on obstructive sleep apnea, has quite a few publications and is co-editor of the primary e-book on HGNS.
Article content material
“As an educational doctor who has devoted my skilled profession to the care of sufferers with sleep disordered respiratory, I used to be privileged to take part within the DREAM U.S. pivotal trial. I used to be initially impressed by the outcomes I noticed in my sufferers after which equally impressed by the info that have been not too long ago reported. As such, I’m honored to have been provided a place to hitch Nyxoah at such an thrilling time. Bilateral hypoglossal nerve stimulation with Genio has great potential and I’m thrilled to work with their gifted crew to make a significant influence on the lives of sufferers with obstructive sleep apnea,” commented Dr. Boon.
“I couldn’t be extra excited to have Dr. Boon be part of Nyxoah. He is among the pioneers in hypoglossal nerve stimulation and his choice to develop into Nyxoah’s Chief Medical Officer displays Genio’s capacity to enhance the lives of OSA sufferers,” commented Olivier Taelman, Chief Government Officer. “Dr. Boon will play a vital position as we put together to enter the U.S. market and obtain our mission of creating sleep easy once more.”
About Nyxoah
Nyxoah is a medical know-how firm centered on the event and commercialization of modern options to deal with Obstructive Sleep Apnea (OSA). Nyxoah’s lead answer is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation remedy for OSA, the world’s most typical sleep disordered respiratory situation that’s related to elevated mortality danger and cardiovascular comorbidities. Nyxoah is pushed by the imaginative and prescient that OSA sufferers ought to take pleasure in restful nights and really feel enabled to dwell their life to its fullest.
Article content material
For extra data, please go to http://www.nyxoah.com/.
Warning – CE marked since 2019. Investigational system in the USA. Restricted by U.S. federal legislation to investigational use in the USA.
Ahead-looking statements
Sure statements, beliefs and opinions on this press launch are forward-looking, which replicate the Firm’s or, as acceptable, the Firm administrators’ or managements’ present expectations concerning the Genio® system; deliberate and ongoing medical research of the Genio® system; the potential benefits of the Genio® system; Nyxoah’s objectives with respect to the event, regulatory pathway and potential use of the Genio® system; the utility of medical information in doubtlessly acquiring FDA approval of the Genio® system; and the Firm’s outcomes of operations, monetary situation, liquidity, efficiency, prospects, progress and techniques. By their nature, forward-looking statements contain quite a few dangers, uncertainties, assumptions and different components that would trigger precise outcomes or occasions to vary materially from these expressed or implied by the forward-looking statements. These dangers, uncertainties, assumptions and components may adversely have an effect on the end result and monetary results of the plans and occasions described herein. Moreover, these dangers and uncertainties embody, however usually are not restricted to, the dangers and uncertainties set forth within the “Danger Components” part of the Firm’s Annual Report on Type 20-F for the 12 months ended December 31, 2023, filed with the Securities and Trade Fee (“SEC”) on March 20, 2024, and subsequent reviews that the Firm recordsdata with the SEC. A large number of things together with, however not restricted to, modifications in demand, competitors and know-how, may cause precise occasions, efficiency or outcomes to vary considerably from any anticipated growth. Ahead trying statements contained on this press launch concerning previous developments or actions usually are not ensures of future efficiency and shouldn’t be taken as a illustration that such developments or actions will proceed sooner or later. As well as, even when precise outcomes or developments are according to the forward-looking statements contained on this press launch, these outcomes or developments might not be indicative of outcomes or developments in future intervals. No representations and warranties are made as to the accuracy or equity of such forward-looking statements. Because of this, the Firm expressly disclaims any obligation or enterprise to launch any updates or revisions to any forward-looking statements on this press launch on account of any change in expectations or any change in occasions, circumstances, assumptions or circumstances on which these forward-looking statements are based mostly, besides if particularly required to take action by legislation or regulation. Neither the Firm nor its advisers or representatives nor any of its subsidiary undertakings or any such individual’s officers or workers ensures that the assumptions underlying such forward-looking statements are free from errors nor does both settle for any duty for the long run accuracy of the forward-looking statements contained on this press launch or the precise incidence of the forecasted developments. You shouldn’t place undue reliance on forward-looking statements, which communicate solely as of the date of this press launch.
Contacts:
Nyxoah
David DeMartino, Chief Technique Officer
david.demartino@nyxoah.com
+1 310 310 1313
Attachment
Share this text in your social community
[ad_2]
